Despite no strong evidence of clinical benefit, microdosing GLP-1s will likely continue as a strategy for some to profit off of the popular drug class.

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli ...

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.